We propose that PHLDA1+ CAFs contribute to tumor growth and immune modulation by activating protumorigenic signaling pathways—such as PI3K/Akt, TGF-β, and KRAS—which, in turn, may impact patient prognosis and therapeutic response. This evidence concerns the gene KRAS and neoplasm.